These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28405843)

  • 1. Quality of life of patients treated for giant cell arteritis: a case-control study.
    Jobard S; Magnant J; Blasco H; Ferreira-Maldent N; Griffoul I; Diot E; Maillot F
    Clin Rheumatol; 2017 Sep; 36(9):2055-2062. PubMed ID: 28405843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).
    Spiera RF; Mitnick HJ; Kupersmith M; Richmond M; Spiera H; Peterson MG; Paget SA
    Clin Exp Rheumatol; 2001; 19(5):495-501. PubMed ID: 11579707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based analysis.
    Broder MS; Sarsour K; Chang E; Collinson N; Tuckwell K; Napalkov P; Klearman M
    Semin Arthritis Rheum; 2016 Oct; 46(2):246-252. PubMed ID: 27378247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Domains of health-related quality of life important to patients with giant cell arteritis.
    Hellmann DB; Uhlfelder ML; Stone JH; Jenckes MW; Cid MC; Guillevin L; Moreland L; Dellaripa PF; Hoffman GS; Merkel PA; Spiera R; Brown L; Hernández-Rodríguez J; Rubin HR
    Arthritis Rheum; 2003 Dec; 49(6):819-25. PubMed ID: 14673969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis.
    Wilson JC; Sarsour K; Collinson N; Tuckwell K; Musselman D; Klearman M; Napalkov P; Jick SS; Stone JH; Meier CR
    Semin Arthritis Rheum; 2017 Apr; 46(5):650-656. PubMed ID: 27839741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual function and quality of life among patients with giant cell (temporal) arteritis.
    Kupersmith MJ; Speira R; Langer R; Richmond M; Peterson M; Speira H; Mitnick H; Paget S
    J Neuroophthalmol; 2001 Dec; 21(4):266-73. PubMed ID: 11756857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis.
    Narváez J; Bernad B; Roig-Vilaseca D; García-Gómez C; Gómez-Vaquero C; Juanola X; Rodriguez-Moreno J; Nolla JM; Valverde J
    Semin Arthritis Rheum; 2007 Aug; 37(1):13-9. PubMed ID: 17360027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis.
    Martínez-Taboada VM; López-Hoyos M; Narvaez J; Muñoz-Cacho P
    Autoimmun Rev; 2014 Aug; 13(8):788-94. PubMed ID: 24667078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Giant cell arteritis (Horton's disease) in very elderly patients aged 80 years and older: A study of 25 cases.
    Muller G; Devilliers H; Besancenot JF; Manckoundia P
    Geriatr Gerontol Int; 2016 Jun; 16(6):679-85. PubMed ID: 26081629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.
    Miyabe C; Miyabe Y; Strle K; Kim ND; Stone JH; Luster AD; Unizony S
    Ann Rheum Dis; 2017 May; 76(5):898-905. PubMed ID: 27927642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is statin exposure associated with occurrence or better outcome in giant cell arteritis? Results from a French population-based study.
    Pugnet G; Sailler L; Bourrel R; Montastruc JL; Lapeyre-Mestre M
    J Rheumatol; 2015 Feb; 42(2):316-22. PubMed ID: 25512477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life of patients with cystic fibrosis assessed by the SF-36 questionnaire.
    Uchmanowicz I; Jankowska-Polańska B; Wleklik M; Rosinczuk-Tonderys J; Dębska G
    Pneumonol Alergol Pol; 2014; 82(1):10-7. PubMed ID: 24391066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis.
    Wilson JC; Sarsour K; Collinson N; Tuckwell K; Musselman D; Klearman M; Napalkov P; Jick SS; Stone JH; Meier CR
    Semin Arthritis Rheum; 2017 Jun; 46(6):819-827. PubMed ID: 28040244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of corticosteroid-resistant giant cell arteritis.
    Wilke WS; Hoffman GS
    Rheum Dis Clin North Am; 1995 Feb; 21(1):59-71. PubMed ID: 7732174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delays in recognition and management of giant cell arteritis: results from a retrospective audit.
    Ezeonyeji AN; Borg FA; Dasgupta B
    Clin Rheumatol; 2011 Feb; 30(2):259-62. PubMed ID: 21086005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron Emission Tomography/Computerized Tomography in Newly Diagnosed Patients with Giant Cell Arteritis Who Are Taking Glucocorticoids.
    Clifford AH; Murphy EM; Burrell SC; Bligh MP; MacDougall RF; Heathcote JG; Castonguay MC; Lee MS; Matheson K; Hanly JG
    J Rheumatol; 2017 Dec; 44(12):1859-1866. PubMed ID: 28916549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis.
    Narváez J; Bernad B; Gómez-Vaquero C; García-Gómez C; Roig-Vilaseca D; Juanola X; Rodriguez-Moreno J; Nolla JM; Valverde J
    Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S57-62. PubMed ID: 18799055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica.
    van der Geest KS; Abdulahad WH; Chalan P; Rutgers A; Horst G; Huitema MG; Roffel MP; Roozendaal C; Kluin PM; Bos NA; Boots AM; Brouwer E
    Arthritis Rheumatol; 2014 Jul; 66(7):1927-38. PubMed ID: 24623536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.
    Hoffman GS; Cid MC; Hellmann DB; Guillevin L; Stone JH; Schousboe J; Cohen P; Calabrese LH; Dickler H; Merkel PA; Fortin P; Flynn JA; Locker GA; Easley KA; Schned E; Hunder GG; Sneller MC; Tuggle C; Swanson H; Hernández-Rodríguez J; Lopez-Soto A; Bork D; Hoffman DB; Kalunian K; Klashman D; Wilke WS; Scheetz RJ; Mandell BF; Fessler BJ; Kosmorsky G; Prayson R; Luqmani RA; Nuki G; McRorie E; Sherrer Y; Baca S; Walsh B; Ferland D; Soubrier M; Choi HK; Gross W; Segal AM; Ludivico C; Puechal X;
    Arthritis Rheum; 2002 May; 46(5):1309-18. PubMed ID: 12115238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis after long-term corticosteroid treatment of giant cell arteritis.
    Andersson R; Rundgren A; Rosengren K; Bengtsson BA; Malmvall BE; Mellström D
    J Intern Med; 1990 Jun; 227(6):391-5. PubMed ID: 2351926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.